YN350079 UM-164 903564-48-7

UM-164 is a highly potent, dual c-Src/p38inhibitor of c-Src with a binding constant Kd of 2.7 nM for c-Src and inhibits both p38α and p38β.

YN350040 Talmapimod 309913-83-5

Talmapimod (SCIO-469) is an orally active, selective, and ATP-competitivep38αinhibitor with an IC50 of 9nM. Talmapimod shows about 10-fold selectivity over p38β, and at least 2000-fold selectivity over a panel of 20 other ...

YN350025 SB 202190 152121-30-7

SB202190 (FHPI) is a potent p38 MAPK inhibitor targeting p38α/β with IC50 of 50 nM/100 nM in cell-free assays, sometimes used instead of SB 203580 to investigate potential roles for SAPK2a/p38 in vivo.

YN350162 RWJ-67657 215303-72-3

RWJ-67657 (JNJ 3026582) is an orally active and selective p38α and p38β MAPK inhibitor with IC50s of 1 and 11μM, respectively. RWJ-67657 displays no activity at p38γ and p38δ, and exhibits cardio protective effe...

YN350087 p38α inhibitor 1 1034189-82-6

p38α inhibitor 1 is ap38αinhibitor extracted from patent WO 2008076265 A1.

YN350091 MW-150 1628502-91-9

MW150 (MW01-18-150SRM) is a selective, CNS penetrant, and orally active inhibitor ofp38α MAPKwith a Ki of 101nM. MW-150 inhibits the ability of the endogenous p38α MAPK to phosphorylate an endogenous substrate MK...

YN350028 Neflamapimod 209410-46-8

VX-745 is a potent and selective inhibitor of p38α with IC50 of 10 nM, 22-fold greater selectivity versus p38β and no inhibition to p38γ.

YN350041 TAK-715 303162-79-0

TAK-715 is a p38 MAPK inhibitor for p38α with IC50 of 7.1 nM, 28-fold more selective for p38α over p38β, no inhibition to p38γ/δ, JNK1, ERK1, IKKβ, MEKK1 or TAK1. Phase 2.

YN350026 Doramapimod 285983-48-4

Doramapimod (BIRB 796) is a  pan-p38 MAPK inhibitor with IC50 of  38 nM, 65 nM, 200 nM and 520 nM for p38α/β/γ/δ in cell-free assays, and binds p38α with Kd of 0.1 nM in THP-1 cells, 330-fold greater se...